Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial

JAMA

Volumn 297, Issue 3, 2007, Pages 267-277

  Oettle, Helmut ^a   Post, Stefan ^b   Neuhaus, Peter ^a   Gellert, Klaus ^c   Langrehr, Jan ^a   Ridwelski, Karsten ^d   Schramm, Harald ^e   Fahlke, Joerg ^f   Zuelke, Carl ^g   Burkart, Christof ^h   Gutberlet, Klaus ⁱ   Kettner, Erika ^d   Schmalenberg, Harald ^j   Weigang Koehler, Karin ^k   Bechstein, Wolf Otto ^l   Niedergethmann, Marco ^b   Schmidt Wolf, Ingo ^m   Roll, Lars ^a   Doerken, Bernd ^a   Riess, Hanno ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c SANA KLINIKUM OFFENBACH   (Germany)

^d City Hospital   (Germany)

^e Department of Surgery   (Germany)

^f UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^g UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ Center for Pediatrics and Adolescent Medicine   (Germany)

^j JENA UNIVERSITY HOSPITAL   (Germany)

^k Nord Hospital   (Germany)

^l UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^m UNIVERSITY HOSPITAL BONN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER GRADING; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EDEMA; FEMALE; HUMAN; INFECTION; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTPATIENT DEPARTMENT; PANCREAS CANCER; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE; TOXICITY; VOMITING;

EID: 33846405332     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.3.267     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
3. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 1993;72:2118-2123.
4. Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg. 1996;171:118-124.
5. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1-7.
6. Bonadonna G, Moliterni A, Zambetti M, et al. 30 Years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study [Epub January 13, 2005]. BMJ. 2005;330:217.
7. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21:1431-1439.
8. Martin M, Pienkowski T, Mackey J, et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302-2313.
9. Leichman CG. Adjuvant therapy for colon cancer 2005: new options in the twenty-first century. Surg Oncol Clin North Am. 2006;15:159-173.
10. Gramont A. Adjuvant therapy of stage II and III colon cancer. Semin Oncol. 2005;32(suppl 8):11-14.
11. Gonzalez RJ, Mansfield PF. Adjuvant and neoadjuvant therapy for gastric cancer. Surg Clin North Am. 2005;85:1033-1051.
12. Kosuge T, Kiuchi T, Mukai K, Kakizoe T; Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP). A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol. 2006;36:159-165.
13. Neoptolemos JP, Stocken DD, Friess H, et al; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
14. Takada T, Amano H, Yasuda H, et al; Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? a phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685-1695.
15. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-782.
16. Bakkevold KE, Arnesjo B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomised multicentre study. Eur J Cancer. 1993;29A:698-703.
17. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899-903.
18. Aapro MS, Martin C, Hatty S. Gemcitabine - a safety review. Anticancer Drugs. 1998;9:191-201.
19. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
20. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients. J Chronic Dis. 1981;34:585-597.
21. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21:195-200.
22. Ducreux M, Rougier P, Pignon JP, et al; Groupe Digestif of the Federation Nationale des Centres de Lutte Contre le Cancer Digestif. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol. 2002;13:1185-1191.
23. Oettle H, Arnold D, Hempel C, Riess H. The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anticancer Drugs. 2000;11:771-786.
24. Tempero MA, Behrman S, Ben-Josef E, et al; National Comprehensive Cancer Network. Pancreatic adenocarcinoma: clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005;3:598-626.
25. Oettle H, Riess H. Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer. 2002;95(4 suppl):912-922.
26. Regine WF, Winter KW, Abrams R, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma [oral presentation]. J Clin Oncol. 2006;24(June 20 suppl 18S):4007.